---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-117256"
form_type: "8-K"
ticker: "TOVX"
cik: "0000894158"
company_name: "Theriva Biologics, Inc."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-22T00:27:42.932855+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Theriva Biologics Q3 2022 cash $50.5M; FDA clears Phase 2 trial for VCN-01 in PDAC

## Summary
- Cash and cash equivalents $50.5M as of Sep 30, 2022; expected runway into Q1 2024.
- FDA and AEMPS cleared the planned Phase 2 trial of VCN-01 in pancreatic ductal adenocarcinoma patients.
- SYN-004 Phase 1b/2a in allo-HCT: positive DSMC review for Cohort 1; first patient dosed in Cohort 2 (Oct 2022).
- Company rebranded as Theriva Biologics and began trading under ticker TOVX on NYSE American in October 2022.
- Anticipated near-term milestones: initiate VIRAGE Phase 2 for VCN-01 in PDAC Q4 2022; pre-IND meeting for retinoblastoma early 2023.

## SEC filing metadata
- accession: 0001104659-22-117256
- form_type: 8-K
- ticker: TOVX
- cik: 0000894158
- company_name: Theriva Biologics, Inc.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/894158/000110465922117256/0001104659-22-117256-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/894158/000110465922117256/tm2230285d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-117256
- JSON: https://secwatch.observer/filing/0001104659-22-117256.json
- Plain text: https://secwatch.observer/filing/0001104659-22-117256.txt

## Key facts
- Earnings Releases
  Theriva Biologics, Inc. reported financial results for for the quarter ended September 30, 2022.
  - Period: for the quarter ended September 30, 2022
  - Result: reported results
  source text: On November 10, 2022, Theriva Biologics, Inc., a Nevada corporation (the “Registrant”) issued a press release that included financial information for its quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/894158/000110465922117256/0001104659-22-117256-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.